Get the Stockscreener App
29.81
0.60%
-0.18
After Hours:
29.81
Stoke Therapeutics Inc stock is traded at $29.81, with a volume of 714.01K.
It is down -0.60% in the last 24 hours and down -5.87% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$29.99
Open:
$29.41
24h Volume:
714.01K
Relative Volume:
0.88
Market Cap:
$1.92B
Revenue:
$32.08M
Net Income/Loss:
$-169.77M
P/E Ratio:
-10.49
EPS:
-2.8418
Net Cash Flow:
$-147.70M
1W Performance:
-5.72%
1M Performance:
-5.87%
6M Performance:
-13.39%
1Y Performance:
+51.86%
1-Day Range:
$29.14
$30.03
1-Week Range:
$29.14
$32.17
52-Week Range:
$19.55
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
29.81 | 2.03B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-05-26 | Initiated | Guggenheim | Buy |
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
STOK Reinstated by JP Morgan -- Price Target Set at $40 - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Goldminenunternehmen, Ross Stores, Stoke Therapeutics - TradingView
STOK Looks 225.6% Overvalued on GF Value™ - GuruFocus
Why is Stoke Therapeutics stock gaining today? By Investing.com - Investing.com Canada
Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 7.9%What's Next? - MarketBeat
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke (STOK) Results Breakdown: The Available Earnings Metric Delivers a Miss in the Reported Period; Share Response: The Stock Records a 2.77% Increase in the Latest ReadingPerformance Review - Vinanet
Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)? - simplywall.st
Stoke (STOK) Quarterly Figures: EPS Falls Short of Its Estimate for the Current Session; Share Move: The Stock Gains 2.64% in the Current UpdateLow Estimate Range - Vinanet
Stoke Therapeutics general counsel Allan sells $91,639 in stock By Investing.com - Investing.com Australia
Stoke therapeutics CMO Barry Ticho sells $152k in stock By Investing.com - Investing.com Australia
Stoke Therapeutics’ director Kaye sells $402,528 in shares By Investing.com - Investing.com Australia
Stoke Therapeutics general counsel Allan sells $91,639 in stock - Investing.com
Stoke Therapeutics’ director Kaye sells $402,528 in shares - Investing.com
Stoke therapeutics CMO Barry Ticho sells $152k in stock - Investing.com
Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells 4,767 Shares of Stock - MarketBeat
Stoke Therapeutics (STOK) insider sale tied to tax withholding - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) CMO gets 10,000 shares, sells some for taxes - Stock Titan
Stoke Therapeutics (STOK) director share sale tied to taxes - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke (STOK) Session-Level Review: Closes 0.70% Higher at $32.35 on the Day; Nearby Levels: Price Remains Between $30.73 Support and $33.97 Resistance on the DayEarnings Beat Stocks - Vinanet
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts - TradingView
Stoke Therapeutics (STOK) gets 6.5% stake disclosure from Lynx1 Capital - Stock Titan
Trading Systems Reacting to (STOK) Volatility - Stock Traders Daily
Stoke Therapeutics (STOK) Slips 0.99% to $32.65 as Shares Consolidate Between Key Support and ResistanceWeak Sell Signals - Vinanet
Stoke Therapeutics (STOK): TD Bank, TD Securities disclose 4.9% equity stake - Stock Titan
Stoke Therapeutics at canaccord growth conference: trial momentum builds By Investing.com - Investing.com Canada
Stoke Therapeutics at canaccord growth conference: trial momentum builds - Investing.com
Stoke Therapeutics (STOK) Short Interest & Short Float | Updated Aug 2026 $STOK - MarketBeat
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript - The Globe and Mail
Stoke Therapeutics, Inc. $STOK Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - The National Law Review
Stoke Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:STOK) 2026-08-07 - Seeking Alpha
Stoke Therapeutics Inc (STOK) Stock News Today - TradingKey
Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 43.5% Upside In Biotech's Genetic Revolution - DirectorsTalk Interviews
What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing? - Yahoo Finance
FMR LLC discloses 8.5% Stoke Therapeutics (STOK) ownership in Schedule 13G/A - Stock Titan
Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report - simplywall.st
Q3 EPS Estimates for Stoke Therapeutics Cut by HC Wainwright - MarketBeat
Stoke Therapeutics (STOK) CMO sells 7,176 shares under 10b5-1 plan - Stock Titan
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $40 to $60 - Moomoo
Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics CMO Barry Ticho disposes of USD 208,707 in common shares - Bitget
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - marketscreener.com
Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
STOK Maintained by Canaccord Genuity -- Price Target Lowered to $58 - GuruFocus
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results - webull.com
STOK Maintains Rating by Wedbush -- Price Target Raised to $40 - GuruFocus
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Stoke Therapeutics Inc Stock (STOK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ticho Barry | CHIEF MEDICAL OFFICER |
Aug 18 '26 |
Sale |
32.03 |
4,767 |
152,690 |
25,655 |
| Kaye Edward M. MD | Director |
Aug 14 '26 |
Option Exercise |
0.00 |
26,250 |
0 |
137,124 |
| Kaye Edward M. MD | Director |
Aug 18 '26 |
Sale |
32.03 |
12,567 |
402,528 |
124,557 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 14 '26 |
Option Exercise |
0.00 |
6,000 |
0 |
24,086 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 18 '26 |
Sale |
32.03 |
2,861 |
91,639 |
21,225 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Aug 03 '26 |
Sale |
29.04 |
7,176 |
208,385 |
20,422 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):